• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CADL alert in real time by email
    SC 13G 1 tm2431336d1_sc13g.htm SC 13G

    CUSIP No: 137404109

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ______________________

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. ____)*

     

    Candel Therapuetics, Inc.
    (Name of Issuer)

     

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

     

    137404109
    (CUSIP Number)

     

    December 13, 2024

    (Date of Event Which Requires Filing of this statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

    ________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No: 137404109

     

    (1) NAMES OF REPORTING PERSONS
       
      CVI Investments, Inc.
       
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (SEE INSTRUCTIONS)
      (a)  ¨
      (b)  ¨
       
    (3) SEC USE ONLY
       
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Cayman Islands

     

    NUMBER OF (5)  SOLE VOTING POWER
       
    SHARES 0
       
    BENEFICIALLY (6)  SHARED VOTING POWER **
       
    OWNED BY 2,350,000
       
    EACH (7)  SOLE DISPOSITIVE POWER
       
    REPORTING 0
       
    PERSON WITH (8)  SHARED DISPOSITIVE POWER **
       
      2,350,000

     

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      2,350,000
       
    (10) CHECK BOX IF THE AGGREGATE AMOUNT
      IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
     
    (11) PERCENT OF CLASS REPRESENTED
      BY AMOUNT IN ROW (9)
       
      5.6%
     
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO
       

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

    CUSIP No: 137404109

     

    (1) NAMES OF REPORTING PERSONS
       
      Heights Capital Management, Inc.
       
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (SEE INSTRUCTIONS)
      (a)  ¨
      (b)  ¨
     
    (3) SEC USE ONLY
       
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware

     

    NUMBER OF (5)  SOLE VOTING POWER
       
    SHARES 0
       
    BENEFICIALLY   (6)  SHARED VOTING POWER **
       
    OWNED BY 2,350,000
       
    EACH (7)  SOLE DISPOSITIVE POWER
       
    REPORTING 0
     
    PERSON WITH (8)  SHARED DISPOSITIVE POWER **
       
      2,350,000

     

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      2,350,000
       
    (10) CHECK BOX IF THE AGGREGATE AMOUNT
      IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
       
    (11) PERCENT OF CLASS REPRESENTED
      BY AMOUNT IN ROW (9)
       
      5.6%
       
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO
       

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

    CUSIP No: 137404109

     

    Item 1.

     

    (a) Name of Issuer

     

    Candel Therapeutics, Inc. (the “Company”)

     

    (b) Address of Issuer’s Principal Executive Offices

    117 Kendrick Street, Suite 450, Needham, MA 02494

    Item 2(a). Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.01 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d) Title of Class of Securities

     

    Common stock, $0.01 par value per share

     

    Item 2(e) CUSIP Number

     

    137404109

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)   ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
         

     

     

    CUSIP No: 137404109

     

    (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k)   ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The Company’s Prospectus Supplement (to Prospectus dated August 12, 2022, Registration No. 333-266605), filed on December 13, 2024, indicates there were 42,125,137 Shares outstanding as of the completion of the offering of the Shares referred to therein.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

     

    CUSIP No: 137404109

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No: 137404109

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: December 17, 2024

     

    CVI INVESTMENTS, INC.

     

    By: Heights Capital Management, Inc.

    pursuant to a Limited Power of Attorney, a copy of

    which is attached as Exhibit I hereto

     

    By: /s/ Brian Sopinsky                 

    Name: Brian Sopinsky

    Title: Secretary

     

    HEIGHTS CAPITAL MANAGEMENT, INC.

     

    By: /s/ Brian Sopinsky                

    Name: Brian Sopinsky

    Title: Secretary

     

     

     

     

     

    CUSIP No: 137404109

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney
    II   Joint Filing Agreement
         
         

     

     

     

     

     

      

    Get the next $CADL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CADL

    DatePrice TargetRatingAnalyst
    2/20/2025$25.00Buy
    Citigroup
    2/19/2025$20.00Buy
    Canaccord Genuity
    2/7/2025$15.00Buy
    BofA Securities
    12/2/2022$11.00Buy
    H.C. Wainwright
    11/19/2021$18.00Outperform
    BMO Capital
    8/23/2021$9.00Buy
    UBS
    8/23/2021$22.00Buy
    Jefferies
    8/23/2021$15.00Outperform
    Credit Suisse
    More analyst ratings

    $CADL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

      NEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Maha Radhakrishnan, M.D., to the Company's Board of Directors (Board) effective June 4, 2025. "We are delighted to welcome Maha as a new member of Candel's Board," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. "Her extensive industry experience will be extremely valuable as Candel advances its late-stage oncology programs toward potential approval and commercial de

      6/6/25 8:05:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

      NEEDHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CAN-2409 (aglatimagene besadenovec), the Company's biological immunotherapy lead candidate, for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease. CAN-2409 was also previously granted FDA Fast Track designation for the same indication. The FDA's RMA

      5/28/25 8:05:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

      NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Candel management will host a webcast and conference call on Tuesday, June 3, 2025, at 1:00PM ET. The call will discuss the Company's positive phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer, which demonstrated a statistically significant 30% reduction in disease recurrence compared with placebo when combined with standard-of-care radiation therapy. The discussion will follow Dr.

      5/27/25 8:05:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Candel Therapeutics with a new price target

      Citigroup initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $25.00

      2/20/25 6:59:49 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Canaccord Genuity initiated coverage on Candel Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $20.00

      2/19/25 7:01:43 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities initiated coverage on Candel Therapeutics with a new price target

      BofA Securities initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $15.00

      2/7/25 8:23:12 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Radhakrishnan Maha

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/6/25 4:36:10 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Radhakrishnan Maha

      3 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/6/25 4:31:09 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Barone Francesca exercised 18,000 shares at a strike of $1.55 and sold $281,673 worth of shares (32,146 units at $8.76), decreasing direct ownership by 13% to 96,527 units (SEC Form 4)

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      3/20/25 4:36:03 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Candel Therapeutics Inc.

      SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

      12/17/24 12:30:40 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Candel Therapeutics Inc. (Amendment)

      SC 13G/A - Candel Therapeutics, Inc. (0001841387) (Subject)

      2/9/23 9:59:40 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Candel Therapeutics Inc.

      SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

      2/14/22 4:40:59 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Financials

    Live finance-specific insights

    See more
    • Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

      NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Candel management will host a webcast and conference call on Tuesday, June 3, 2025, at 1:00PM ET. The call will discuss the Company's positive phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer, which demonstrated a statistically significant 30% reduction in disease recurrence compared with placebo when combined with standard-of-care radiation therapy. The discussion will follow Dr.

      5/27/25 8:05:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

      Positive topline data for CAN-2409 viral immunotherapy achieved primary endpoint by demonstrating statistically significant and clinically meaningful benefit when combined with radiation therapy for intermediate-to-high risk, localized prostate cancerThe safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identifiedThe phase 3 clinical trial was conducted under a Special Protocol Assessment (SPA) with the FDA NEEDHAM, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients

      12/11/24 7:00:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

      Expects to announce clinical trial data from multiple oncology programs in the second half of 2023Extends cash runway into second quarter of 2024 NEEDHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. "Our 2022 achievements reaffirm our belief that using our viral immunotherapies to mobilize the patient's immune system to fight cancer represents a promising a

      3/30/23 8:00:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Leadership Updates

    Live Leadership Updates

    See more
    • Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

      NEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Maha Radhakrishnan, M.D., to the Company's Board of Directors (Board) effective June 4, 2025. "We are delighted to welcome Maha as a new member of Candel's Board," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. "Her extensive industry experience will be extremely valuable as Candel advances its late-stage oncology programs toward potential approval and commercial de

      6/6/25 8:05:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

      NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Elizabeth M. Jaffee, M.D., to the Company's Research Advisory Board (RAB). Dr. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, brings her extensive expertise to the RAB, which is important in light of the Company's focus on borderline resectable pancreatic cancer. Dr. Jaffee currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology, Deputy Dire

      3/18/25 8:00:46 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

      MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro

      9/4/24 8:00:00 AM ET
      $CADL
      $EBS
      $MIST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CADL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manning Paul B bought $7,500,000 worth of shares (1,250,000 units at $6.00) (SEC Form 4)

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      12/18/24 4:11:47 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    SEC Filings

    See more
    • Candel Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

      6/6/25 8:11:04 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

      5/28/25 8:10:40 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

      5/22/25 5:12:48 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care